Plus senior pharma hires in the US and Asia in this week's column.
InSilico Medicine, a biopharmaceutical company targeting age-related diseases owned by Deep Knowledge Ventures, has hired leading computer scientist Bhubaneswar (Bud) Mishra. Mishra will join InSilico’s Science Advisory Board.
InSilico’s CEO Alex Zhavoronkov, described Mishra as “one of those rare scientists who excelled in the many fields including physics, engineering, computer science, robotics, finance, genomics, epigenetics, genetics and disease modelling.
“In the course of his career, Dr Mishra has been mentored by many scientific and engineering luminaries and has trained two generations of computer science visionaries now leading various cutting-edge research at DEShaw, Blackstone, Google, and many other leading companies.”
Mishra is a Professor of computer science and mathematics at NYU's Courant Institute of Mathematical Sciences, and Professor of human genetics at Mt. Sinai School of Medicine, as well as a Professor of cell biology at NYU School of Medicine.
His main area of research is applied algorithmics, with more general work in compilers, complex algorithms, robotics, finance, the internet, and biology. InSilico said it had been attracted to Mishra’s work on cancer genetics and the application of mathematical modelling to the processes related to human ageing.
Mishra said he would be joining a “dream team” at InSilico, which includes “leading visionary Dr Charles Cantor, who has 'disrupted' the way we think about biology, biotechnology and bioinformatics.” Cantor recently became Chairman of the Scientific Advisory Board.
Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
in-Pharmatechnologist.com takes a look at the People on the Move this week.
The WHO Executive Board prepares for a special Ebola meeting, CEO leaves troubled biotech, and senior staff...
Novartis's CEO becomes President of EFPIA, a new head of R&D for Genentech, and more People on...